ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Galectin Therapeutics Announces $10 Million Credit Line from Richard E. Uihlein Sufficient to Cover
December 21, 2017Galectin Therapeutics (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced it entered into a $10 million unsecured line of credit facility with stockholder and new director Richard E. Uihlein. -
Galectin Therapeutics' share value plummets by half after NASH drug failure
December 07, 2017Galectin Therapeutics has seen its share value almost halve after its revealed that GR-MD-02, its experimental treatment for non-alcoholic steatohepatitis (NASH) cirrhosis, had missed its primary endpoint in a Phase 2b trial.
Pharma Sources Insight January 2025
